Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$18.65 USD
-0.85 (-4.35%)
Updated Apr 29, 2024 03:57 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Calliditas Therapeutics AB Sponsored ADR (CALT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.00 | $57.00 | $17.00 | 110.26% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Calliditas Therapeutics AB Sponsored ADR comes to $41.00. The forecasts range from a low of $17.00 to a high of $57.00. The average price target represents an increase of 110.26% from the last closing price of $19.50.
Analyst Price Targets (6 )
Broker Rating
Calliditas Therapeutics AB Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/21/2024 | Guggenheim Securities | Vamil Divan | Hold | Hold |
11/27/2023 | H.C. Wainwright & Co. | Arthur He | Strong Buy | Strong Buy |
8/17/2023 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $41.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | -0.14 |